Stansberry Research

Dear Reader,

A thousand doctors, in one room, stood watching the stage in awe.

Some were holding their breath.

We were witnessing medical history.

Onstage, a device was being demonstrated for the first time ever.

If successful… it would treat one of the worst diseases in mankind, and end the suffering of 800,000 Americans.

If approved… it could make investors a 200% gain, beginning Dec. 31^st.

Here's the full story.

Regards,

Dave Lashmet
Senior Analyst, Stansberry Research

P.S. If approval for this new device comes through beginning December 31^st, as I predict, you could make two times your money. Read on.

All contents of this e-mail are copyright 2017 by Stansberry Research. All rights reserved. Reproducing any part of this document is prohibited without the express written consent of Porter Stansberry. Protected by U.S. Copyright Law {Title 17 U.S.C. Section 101 et seq., Title 18 U.S.C. Section 2319}: Infringements can be punishable by up to five years in prison and $250,000 in fines.

DISCLAIMER: The work included in this publication is based on SEC filings, current events, interviews, and corporate press releases. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. The views expressed in this publication do not necessarily reflect the views of Stansberry Research.

You're receiving this email at newsletter@newslettercollector.com. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday-Friday between 9:00 a.m. and 5:00 p.m. Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles Street Baltimore, MD 21201. If you wish to contact us by email, please do not reply to this message but instead go to info@stansberrycustomerservice.com.

To unsubscribe from this mailing, click here: Unsubscribe